Compare Medpace Holdings Inc (MEDP) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs T Rowe Price Group Inc — how do they compare? Medpace Holdings Inc trades at $598.47 (market cap $16.90B), while T Rowe Price Group Inc trades at $111.53 (market cap $24.26B). The key difference: T Rowe Price Group Inc is the larger of the two by market cap, and T Rowe Price Group Inc pays a 4.57% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | TROW | |
|---|---|---|
Market Cap | $16.90B | $24.26B |
Sector | Technology | Financials |
52-Week High | $620.59 | $121.68 |
52-Week Low | $393.42 | $86.19 |
Enterprise Value | $16.52B | $21.46B |
Dividend Yield | — | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
T. Rowe Price Group (TROW) trades at $113.77, down 0.22% on the day, with a neutral technical signal and mixed analyst sentiment. The stock shows strong profitability with a 29.26% net income margin and a P/E of 11.42, indicating potential undervaluation. Recent Q2 2026 earnings beat expectations at $2.57 per share, supported by record assets under management and higher advisory fees, though expenses and net outflows remain headwinds.
The outlook is cautiously optimistic with earnings growth and dividend stability offering upside, but risks include expense pressures and market volatility. Analyst consensus is a Hold with a $112.17 price target, near the current price, suggesting limited near-term momentum. Institutional activity shows mixed positioning, reflecting balanced risk-reward.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
